Pacira Pharmaceuticals Reports 2016 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nvidia's revenue forecast lifts Wall Street; investors eye the Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Pacira Pharmaceuticals (PCRX) Data 'Increases Takeout Valuation' - Mizuho
March 1, 2017 10:30 AM ESTShares of Pacira Pharmaceuticals (NASDAQ: PCRX) are up 12% following positive Phase IV data from the TKA study. The study hit both of its co-primary endpoints (demonstrating statistically significant benefits for greater pain reduction (p=0.0381) and lower opioid utilization (p=0.0048). Secondary endpoints such as... More
Pacira Pharma (PCRX) Tops Q4 EPS by 8c
March 1, 2017 7:31 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.09, $0.08 better than the analyst estimate of $0.01. Revenue for the quarter came in at $72.9 million versus the consensus estimate of $73.07 million.
We made important progress in 2016 advancing our three-part EXPAREL growth strategy and setting the stage for continued success, said Dave Stack, chief executive officer and chairman of Pacira. We have multiple, major milestones on track for 2017, including the positive topline results reported today from our Phase 4 study in TKA. Our collaboration with DePuy Synthes is off to a strong start and will allow us to... More
